Hyperliquid Labs has begun unstaking a tranche of HYPE tokens valued at $320 million, with the entire amount intended for an over-the-counter (OTC) purchase involving an institutional player, according to a report from BSCN citing internal communication shared on Discord.

HYPE is the native token of Hyperliquid, a decentralized trading platform for perpetual futures. Unstaking refers to the process of withdrawing tokens from a staked position, after which they can typically be transferred or deployed by the holder. In this instance, the reported destination of the tokens is a direct institutional transaction rather than open-market trading.

$320 Million HYPE Tranche Set for OTC Purchase

The unstaking involves HYPE tokens allocated under Hyperliquid's planned monthly release for the core team. Rather than being directed toward open-market trading, the full tranche is reportedly intended for an OTC transaction.

OTC transactions are conducted directly between counterparties rather than through a public exchange order book. This structure is the customary route for large block purchases, since size and terms are negotiated bilaterally instead of being filled against public order book liquidity. In this case, BSCN reported that the planned transaction involves an institutional player, although the post did not identify the institution involved.

The reported $320 million figure represents the value of the HYPE tokens in the tranche as cited by BSCN. The source did not disclose the number of HYPE tokens being unstaked, nor did it specify the price used to calculate the stated value.

Part of the Monthly Core Team Release

The unstaking forms part of Hyperliquid Labs' planned monthly core team token release, according to the report. The timing therefore falls within an existing release mechanism rather than representing a separately announced token allocation.

BSCN cited internal communication shared on Discord as the source for information about how the tranche is intended to be used. The communication reportedly states that the entire amount will be allocated to the OTC purchase. Once the unstaking process completes, the tokens would be in a position to be transferred directly to the OTC counterparty rather than routed through a public venue.

The identity of the institutional buyer was not disclosed in the source material. No additional details were provided regarding the transaction's execution date, settlement terms, or the price agreed between the parties.

Institutional OTC Purchase Remains the Stated Use

The reported transaction stands out for the stated destination of the unstaked tokens: an institutional OTC purchase rather than general market distribution. Because the arrangement is described as an OTC transaction, the reported deal is separate from activity conducted through public exchange order books.

BSCN did not, however, provide details that would establish the identity of the counterparty or the final terms of the transaction. Confirmation of those elements — the buyer, the execution date, the settlement terms, and the agreed price — would need to come from the parties involved, as the report did not include them.

For now, the available information indicates that Hyperliquid Labs has begun unstaking the $320 million HYPE tranche as part of its monthly core team release, with the full amount intended for an OTC purchase involving an institutional player.

Sources

• BSCN report on X
• Original article on Hokanews, published September 30, 2026, written by Ethan Collins